Treatment resistance and metastasis depend on cellular plasticity. In this process the cancer cells switch from a non-motile and well-differentiated phenotype to a migratory and de-differentiated phenotype. We are investigating the intrinsic and extrinsic factors/mechanisms involved in such cellular plasticity aiming to identify molecular nodes that can be utilized as targets for anti-cancer treatment. The project group headed by Prof Kristin Austlid Taskén is studying neuronal differentiation of prostate cancer, while the Lina Prasmickaite project group is focusing on phenotype switching in breast cancer and melanomas.
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion
Lab Invest, 100 (7), 928-944
Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer
Biomacromolecules, 21 (4), 1489-1498